Conversion to everolimus in kidney transplant recipients: a safe and simple procedure.
暂无分享，去创建一个
M. Arias | J. Ruiz | A. Sánchez-Fructuoso | J. Cotorruelo | E. Rodrigo | J. Conesa | N. Calvo | A. Barrientos | C. Gómez‐Alamillo
[1] A. Pariente,et al. Proteinuria Following a Switch from Calcineurin Inhibitors to Sirolimus , 2005, Transplantation.
[2] F. Diekmann,et al. Evolution of proteinuria after conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients: a multicenter study. , 2005, Transplantation proceedings.
[3] L. Rostaing,et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[4] J. Pascual. Concentration-Controlled Everolimus (Certican): Combination with Reduced Dose Calcineurin Inhibitors , 2005, Transplantation.
[5] Mai-Szu Wu,et al. Rapamycin in patients with chronic renal allograft dysfunction , 2005, Clinical transplantation.
[6] C. Ponticelli,et al. Everolimus and Reduced-Exposure Cyclosporine in de novo Renal-Transplant Recipients: A Three-Year Phase II, Randomized, Multicenter, Open-Label Study , 2004, Transplantation.
[7] K. Budde,et al. Predictors of Success in Conversion from Calcineurin Inhibitor to Sirolimus in Chronic Allograft Dysfunction , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.